CTI BioPharma to Present at 27th Annual Piper Jaffray Healthcare Conference.
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015, at 12:00 p.m. EST/6:00 p.m. CET in New York.
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
Contacts: Monique Greer +1 206-272-4343 firstname.lastname@example.org
Ed Bell +1 206-272-4345 email@example.com
Logo - http://photos.prnewswire.com/prnh/20140529/92480
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-27th-annual-piper-jaffray-healthcare-conference-300183582.html
SOURCE CTI BioPharma Corp.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Conference news|
|Date:||Nov 24, 2015|
|Previous Article:||Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolled.|
|Next Article:||Boeing, EVA Airways Finalize Taiwan's Largest Ever Commercial Airplane Purchase.|